Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities
Dane Cheasley(The University of Melbourne), Ian Campbell(The University of Sydney), Mark Carey(University of British Columbia), Kylie L. Gorringe(The University of Melbourne), Diane Provencher(Centre Hospitalier de l’Université de Montréal), Prue E. Allan(Epworth Hospital), Anna DeFazio(The University of Sydney), Amy Dawson(University of British Columbia), David D.L. Bowtell(The University of Melbourne), Neville F. Hacker(New South Wales Department of Health), Anne‐Marie Mes‐Masson(Centre Hospitalier de l’Université de Montréal), Abhimanyu Nigam(The University of Melbourne), Cécile Le Page(Institut Universitaire en Santé Mentale de Québec), Magnus Zethoven(Peter MacCallum Cancer Centre), David G. Huntsman(BC Cancer Agency), Martin Köbel(University of Calgary), Dariush Etemadmoghadam(Peter MacCallum Cancer Centre), Sally M. Hunter(Peter MacCallum Cancer Centre), Marta Llauradó Fernández(University of British Columbia), Yunkai Gao(Tongji University), Timothy Semple(The University of Melbourne)
Cited by 127
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k